EP1011705A4 - Konjugate, die auf den interleukin-2 rezeptor zielgerichtet sind - Google Patents

Konjugate, die auf den interleukin-2 rezeptor zielgerichtet sind

Info

Publication number
EP1011705A4
EP1011705A4 EP98939226A EP98939226A EP1011705A4 EP 1011705 A4 EP1011705 A4 EP 1011705A4 EP 98939226 A EP98939226 A EP 98939226A EP 98939226 A EP98939226 A EP 98939226A EP 1011705 A4 EP1011705 A4 EP 1011705A4
Authority
EP
European Patent Office
Prior art keywords
interleukin
receptor
conjugates targeted
conjugates
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98939226A
Other languages
English (en)
French (fr)
Other versions
EP1011705A2 (de
Inventor
Ramesh K Prakash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Finance LLC
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of EP1011705A2 publication Critical patent/EP1011705A2/de
Publication of EP1011705A4 publication Critical patent/EP1011705A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98939226A 1997-08-05 1998-08-05 Konjugate, die auf den interleukin-2 rezeptor zielgerichtet sind Withdrawn EP1011705A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91404297A 1997-08-05 1997-08-05
US914042 1997-08-05
PCT/US1998/016290 WO1999007324A2 (en) 1997-08-05 1998-08-05 Conjugates targeted to the interleukin-2 receptor

Publications (2)

Publication Number Publication Date
EP1011705A2 EP1011705A2 (de) 2000-06-28
EP1011705A4 true EP1011705A4 (de) 2000-09-20

Family

ID=25433849

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98939226A Withdrawn EP1011705A4 (de) 1997-08-05 1998-08-05 Konjugate, die auf den interleukin-2 rezeptor zielgerichtet sind

Country Status (5)

Country Link
EP (1) EP1011705A4 (de)
JP (1) JP2003516305A (de)
AU (1) AU8769898A (de)
CA (1) CA2299368A1 (de)
WO (1) WO1999007324A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
AU782309B2 (en) * 1999-03-08 2005-07-21 Gerhart Graupner Methods and compositions for targeted drug delivery
WO2001060848A2 (en) * 2000-02-18 2001-08-23 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008263A1 (en) * 1994-09-13 1996-03-21 Theratech, Inc. Intracellular delivery of chemical agents to a specific cell type
WO1997033618A1 (en) * 1996-03-15 1997-09-18 Theratech, Inc. Targeting macromolecular prodrugs to t lymphocytes
WO2000007543A2 (en) * 1998-08-04 2000-02-17 Watson Laboratories, Inc.-Utah Conjugates targeted to the interleukin-2 receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5149528A (en) * 1987-04-10 1992-09-22 Zymogenetics, Inc. Cytotoxic protein from Trichosanthes kirilowii
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5059413A (en) * 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5571507A (en) * 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008263A1 (en) * 1994-09-13 1996-03-21 Theratech, Inc. Intracellular delivery of chemical agents to a specific cell type
WO1997033618A1 (en) * 1996-03-15 1997-09-18 Theratech, Inc. Targeting macromolecular prodrugs to t lymphocytes
WO2000007543A2 (en) * 1998-08-04 2000-02-17 Watson Laboratories, Inc.-Utah Conjugates targeted to the interleukin-2 receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9907324A3 *

Also Published As

Publication number Publication date
EP1011705A2 (de) 2000-06-28
WO1999007324A3 (en) 1999-04-15
CA2299368A1 (en) 1999-02-18
WO1999007324A2 (en) 1999-02-18
AU8769898A (en) 1999-03-01
JP2003516305A (ja) 2003-05-13

Similar Documents

Publication Publication Date Title
GB9713980D0 (en) New conjugates
HUP0300548A3 (en) Polyol-ifn-betha conjugates
EP1001702A4 (de) Orthesen
GB9701413D0 (en) Novel device
GB9826359D0 (en) Novel receptors
EP0985044A4 (de) Antikrebs impfstoff
IL133920A0 (en) Trail receptor
GB9720986D0 (en) Bracket
EP0973800A4 (de) Neuartiger rezeptor
GB2324460B (en) Bracket member
EP1011705A4 (de) Konjugate, die auf den interleukin-2 rezeptor zielgerichtet sind
GB2330376B (en) Improvements relating to connection devices
HK1041832A1 (zh) 血紅蛋白-抗氧化劑輟合物
GB9700664D0 (en) Anti-cancer agents
EP1092017A4 (de) Neuer gaba-b rezeptor
EP1083909A4 (de) hCEPR REZEPTOR
GB9717229D0 (en) Novel device
ZA987181B (en) Conjugates targeted to the interleukin-2-receptor
GB9803450D0 (en) Mounted device assembly
EP1109565A4 (de) Gabab1aa rezeptor
TW326754U (en) Improved attached bookmarker structure
GB9813279D0 (en) Modified receptor
GB9818451D0 (en) Conjugates
GB9825849D0 (en) Receptor
GB9719470D0 (en) Nocotinic receptors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000217

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000803

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/00 A, 7A 61K 38/04 B, 7A 61K 38/08 B, 7A 61K 47/48 B, 7C 07K 7/06 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020301